13F HOLDINGS REPORT
Foresite Capital Management IV, LLC
Quarter ended Q3 2024 · Filed November 14, 2024 · Accession 0001104659-24-118737
Total Value
$153.0M
Positions
5
Other Managers
0
Confidential Omitted
No
Holdings (5)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Pharvaris N.V. | PHVS | 4,397,881 | $81.4M | 53.23% |
| 2 | Kura Oncology, Inc. | KURA | 1,849,947 | $36.1M | 23.62% |
| 3 | Syndax Pharmaceuticals, Inc. | SNDX | 875,000 | $16.8M | 11.01% |
| 4 | Lyell Immunopharma, Inc. | LYEL | 8,325,000 | $11.5M | 7.51% |
| 5 | Relay Therapeutics Inc. | RLAY | 1,000,000 | $7.1M | 4.63% |